Trial Profile
A Randomized, Double-blind, Placebo-Controlled Study With Varespladib Infusion (A-001) in Subjects With Sickle Cell Disease and Vaso-Occlusive Crisis for the Prevention of Acute Chest Syndrome At-Risk Subjects.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Varespladib (Primary)
- Indications Acute lung injury
- Focus Therapeutic Use
- Acronyms IMPACTS-2
- Sponsors Anthera Pharmaceuticals
- 28 May 2014 New trial record
- 21 Mar 2012